‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/13910804/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/87A93A/" height="90" width="100%" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>
JAMA Oncology Author Interviews
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
30
00:00:00
/ 00:19:11
30
